Table 2.

Plasma and tumor concentrations of gefitinib and M523595 observed in patients receiving gefitinib 250 mg/d in study BCIRG 103

Patient numberNo. gefitinib dosesGefitinib concentration
M523595 concentration
Plasma (μg/mL)Tumor (μg/g)Plasma (μg/mL)Tumor (μg/g)
61001180.0994.50.0980.03
61002180.22513.10.038NQ
61003170.11012.10.3350.27
61005170.1036.40.1270.03
61006180.1352.80.4670.07
61007160.44012.60.1090.04
61008170.36225.80.0480.05
61009170.1902.30.1870.04
61010270.15311.60.3030.16
61011270.1231.40.061NQ
61013170.0421.40.1160.05
61014230.0481.90.1490.03
61015270.3086.90.8150.21
61016200.0190.20.011NQ
61017140.18710.40.5550.27
61019270.1726.00.060NQ
61023190.2213.40.067NQ
61024180.2987.60.3160.08
61025160.21412.70.6850.26
Mean200.187.50.240.11
Range14–270.02–0.440.2–25.80.01–0.820.00–0.27
  • NOTE: Concentrations of gefitinib and M523595 in each sample were determined using the same HPLC method. Concentrations were below the assay limit of quantification, which was 5 ng/mL for M523595.

    Abbreviation: NQ, not quantifiable.